Mostrar el registro sencillo del ítem
dc.contributor.author | Porcuna, Jesus | |
dc.contributor.author | Mínguez-Martínez, Jorge | |
dc.contributor.author | Ricote, Mercedes | |
dc.date.accessioned | 2022-03-03T09:39:55Z | |
dc.date.available | 2022-03-03T09:39:55Z | |
dc.date.issued | 2021-09-30 | |
dc.identifier.citation | Int J Mol Sci. 2021 Oct; 22(19): 10573 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/13712 | |
dc.description.abstract | Peroxisome proliferator-activated receptors (PPARs) are ligand-modulated nuclear receptors that play pivotal roles in nutrient sensing, metabolism, and lipid-related processes. Correct control of their target genes requires tight regulation of the expression of different PPAR isoforms in each tissue, and the dysregulation of PPAR-dependent transcriptional programs is linked to disorders, such as metabolic and immune diseases or cancer. Several PPAR regulators and PPAR-regulated factors are epigenetic effectors, including non-coding RNAs, epigenetic enzymes, histone modifiers, and DNA methyltransferases. In this review, we examine advances in PPARα and PPARγ-related epigenetic regulation in metabolic disorders, including obesity and diabetes, immune disorders, such as sclerosis and lupus, and a variety of cancers, providing new insights into the possible therapeutic exploitation of PPAR epigenetic modulation. | es_ES |
dc.description.sponsorship | This research was funded by the Ministerio de Ciencia, Innovacion y Universidades (MCNU) (SAF2017-90604-REDT-NurCaMeIn, RTI2018-095928-BI00) and the Comunidad de Madrid (MOIR-B2017/BMD-3684) to MR; the MCNU fellowships to JP (FPU17/01731) and to JM-M (PRE2019-087964). The CNIC is supported by the MCNU and the Pro CNIC Foundation. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject.mesh | Epigenesis, Genetic | es_ES |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | DNA Methylation | es_ES |
dc.subject.mesh | Gene Expression Regulation | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Immune System Diseases | es_ES |
dc.subject.mesh | Metabolic Diseases | es_ES |
dc.subject.mesh | Neoplasms | es_ES |
dc.subject.mesh | PPAR alpha | es_ES |
dc.subject.mesh | PPAR gamma | es_ES |
dc.title | The PPARα and PPARγ Epigenetic Landscape in Cancer and Immune and Metabolic Disorders | es_ES |
dc.title.alternative | The PPAR alpha and PPAR gamma Epigenetic Landscape in Cancer and Immune and Metabolic Disorders | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial 4.0 Internacional | * |
dc.identifier.pubmedID | 34638914 | es_ES |
dc.format.volume | 22 | es_ES |
dc.format.number | 19 | es_ES |
dc.format.page | 10573 | es_ES |
dc.identifier.doi | 10.3390/ijms221910573 | es_ES |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | es_ES |
dc.contributor.funder | Comunidad de Madrid (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1422-0067 | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/1422-0067/22/19/10573/htm | es_ES |
dc.identifier.journal | International journal of molecular sciences | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Señalización de los Receptores Nucleares | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/SAF2017-90604-REDT-NurCaMeIn | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RTI2018-095928-BI00 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/MOIR-B2017/BMD-3684 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/FPU17/01731 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PRE2019-087964 | es_ES |